Andy Atuegbu

This inventor holds 14 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 4 EPO patents, primarily in Antiviral Compounds. Top assignees: Rigel Pharmaceuticals, Incorporated, Prosetta Antiviral, Inc.. Active years: 2011-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andy Atuegbu. Retrieved from https://idiyas.com/inventor/andy-atuegbu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 1)

% Patents Active = 57.1

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 6.8

ph-index = 5

Forward Citations = 110(Granted Patents)

Company Filing History:

8 out of 492

Rigel Pharmaceuticals, Incorporated

patents

6 out of 11

Prosetta Antiviral, Inc.

patents

Years Active: 2011-2019

Loading Chart...

Areas of Expertise:

Anti-HIV Compounds

Pyrimidine-2-Amine

JAK Kinase Inhibitors

Antiviral Compounds

Pyrimidinediamine

Inhibition

JAK Pathway

Pharmaceuticals

Therapeutics

Drug Development

Compounds

Medicinal Chemistry

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10195189 - 2-phenethenyltetrahydro isoquinolines useful as anti-HIV compounds (2019-02-05),

2. 9624229 - Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases (2017-04-18),

3. 9518022 - Anti-HIV compounds (2016-12-13),

4. 9040527 - Pyrimidinediamine kinase inhibitors (2015-05-26),

5. 8828986 - Antiviral compounds (2014-09-09),

6. 8809317 - Antiviral compounds (2014-08-19),

7. 8785434 - Antiviral compounds (2014-07-22),

8. 8759336 - Antiviral compounds (2014-06-24),

9. 8735418 - Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases (2014-05-27),

10. 8518937 - Pyrimidinediamine kinase inhibitors (2013-08-27),

11. 8309566 - Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases (2012-11-13),

12. 8304422 - Compositions and methods for inhibition of the JAK pathway (2012-11-06),

13. 8278299 - Pyrimidinediamine kinase inhibitors (2012-10-02),

14. 7947698 - Compositions and methods for inhibition of the JAK pathway (2011-05-24),

Title: **The Innovative Mind of Andy Atuegbu**

Introduction

Andy Atuegbu, a notable inventor based in Dublin, California, has made significant contributions to the fields of pharmaceuticals and antiviral research. With an impressive portfolio of 14 patents, Atuegbu has focused on developing innovative compounds aimed at treating viral infections and other diseases.

Latest Patents

Among his most recent inventions, Atuegbu has patented tetrahydroisoquinolines, which are recognized for their potential as anti-HIV compounds. This invention provides critical methods for inhibiting the replication of viruses, particularly HIV, and outlines pharmaceutical formulations that incorporate these compounds. Additionally, he holds a patent for pyrimidine-2-amine compounds, which act as inhibitors of JAK kinases. This innovation addresses diseases linked to JAK2 activity, providing a promising avenue for treatment through specific compounds and their acceptable salts.

Career Highlights

Andy Atuegbu's career reflects a strong commitment to pharmaceutical innovation. He has held significant roles in well-regarded companies such as Rigel Pharmaceuticals and Prosetta Antiviral. His work has had meaningful implications for the treatment of viral conditions and has enhanced the understanding of disease mechanisms.

Collaborations

Atuegbu's journey is marked by collaboration with esteemed colleagues, including Somasekhar Bhamidipati and Rajinder Paul Singh. Together, they have pushed the boundaries of research and contributed to the development of groundbreaking therapeutic solutions.

Conclusion

In summary, Andy Atuegbu exemplifies the qualities of a dedicated inventor, continually striving to advance medical science through innovative inventions. His patents not only highlight his expertise in the pharmaceutical domain but also underscore his commitment to tackling serious health challenges. With his ongoing contributions, Atuegbu remains a critical figure in the pursuit of effective treatments for viral diseases.

Profile summary based on public USPTO records.